Stock Events

Stock Events

Intellia Therapeutics 

$12.75
0
-$0.69-5.13% Today

Statistics

Day High
13.5
Day Low
12.13
52W High
-
52W Low
-
Volume
10,963,850
Avg. Volume
-
Mkt Cap
1.48B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19FebExpected
Q3 2025
Next
-1.01
-0.98
-0.95
-0.92
Expected EPS
-0.963195
Actual EPS
N/A

Financials

-896.77%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
115.75MRevenue
-1.04BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NTLA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the CRISPR gene editing space, directly competing with Intellia's gene editing therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is a leader in the development of CRISPR/Cas9 technology, making it a direct competitor in gene editing.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics uses base editing, a form of gene editing that competes with Intellia's CRISPR/Cas9 technology.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, including gene editing, competing in the same space as Intellia.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, an alternative to CRISPR-based gene editing, posing competition in genetic disease treatment.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals develops RNA-targeted therapies, which can be seen as an alternative to CRISPR-based approaches like Intellia's.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on enzyme replacement therapies, which can compete with gene editing for certain genetic disorders.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals collaborates on CRISPR therapies and develops treatments for genetic diseases, competing in similar areas as Intellia.

About

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Dr. John M. Leonard M.D.
Employees
403
Country
US
ISIN
US45826J1051

Listings

F
DE
38I.F
LSE
GB
0JBU.LSE
XNAS
US
NTLA
BOATS
BOATS
NTLA.BOATS

0 Comments

Share your thoughts

FAQ

What is Intellia Therapeutics stock price today?▼
The current price of NTLA.BOATS is $12.75 USD — it has decreased by -5.13% in the past 24 hours. Watch Intellia Therapeutics stock price performance more closely on the chart.
What is Intellia Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Intellia Therapeutics stocks are traded under the ticker NTLA.BOATS.
What is Intellia Therapeutics market cap?▼
Today Intellia Therapeutics has the market capitalization of 1.48B
When is the next Intellia Therapeutics earnings date?▼
Intellia Therapeutics is going to release the next earnings report on February 19, 2026.
What were Intellia Therapeutics earnings last quarter?▼
NTLA.BOATS earnings for the last quarter are -0.92 USD per share, whereas the estimation was -1.01 USD resulting in a +8.48% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Intellia Therapeutics revenue for the last year?▼
Intellia Therapeutics revenue for the last year amounts to 115.75M USD.
What is Intellia Therapeutics net income for the last year?▼
NTLA.BOATS net income for the last year is -1.04B USD.
How many employees does Intellia Therapeutics have?▼
As of February 02, 2026, the company has 403 employees.
In which sector is Intellia Therapeutics located?▼
Intellia Therapeutics operates in the Health Care sector.
When did Intellia Therapeutics complete a stock split?▼
Intellia Therapeutics has not had any recent stock splits.
Where is Intellia Therapeutics headquartered?▼
Intellia Therapeutics is headquartered in Cambridge, US.